Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 March;52(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 March;52(1):50-65

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  ADVANCES IN PET - PART IIFREEfree


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 March;52(1):50-65

Copyright © 2008 EDIZIONI MINERVA MEDICA

language: English

Oncologic PET tracers beyond [18F]FDG and the novel quantitative approaches in PET imaging

Kumar R. 1, Dhanpathi H. 1, Basu S. 2, Rubello D. 3, Fanti S. 4, Alavi A. 2

1 Department of Nuclear Medicine All India Institute of Medical Sciences, New Delhi, India 2 Division of Nuclear Medicine, Department of Radiology University of Pennsylvania School of Medicine Hospital of the University of Pennsylvania Philadelphia, PA, USA 3 Nuclear Medicine Service S. Maria della Misericordia Rovigo Hospital Istituto Oncologico Veneto (IOV)-IRCCS, Italy 4 Nuclear Medicine Department S. Orsola-Malpighi Polyclinic University of Bologna, Bologna, Italy


FULL TEXT  


In this review, we focus on the oncological applications of positron emission tomography (PET) tracers other than [18F]fluoro-2-deoxy-D-glucose (FDG) and the novel quantitative approaches in PET imaging. Oncological non-FDG PET tracers can be broadly categorized into 3 groups: those labeled with 18F, 11C and other non-FDG tracers. Fluorine-18 and 11C are labeled with different aminoacids, substrates involved in fatty acid synthesis, protein synthesis, amino acid transport substrate and tracers linked to nucleic acid synthesis. These tracers are also labeled with specific ligands for receptor imaging (i.e. estrogens, dihydrotestosterone or somatostatin). The other non-FDG radiotracers can be labeled with 68Ga, 60Cu, 64Cu, etc. and are aimed to detect cell hypoxia, bone metabolism and receptor. Many of these have shown promising results in the management of various cancers where FDG has limited role. These radiotracers have more specific mechanism of uptake and is likely be investigated in the near future. In the era of fusion imaging, novel approaches for accurate quantitative analysis include partial volume correction for measured values in small lesions, dual-time point and delayed PET imaging, and global metabolic activity for assessment of various stages of disease. Major changes are likely to occur in the future that may overcome deficiencies that are associated with the current quantitative (standardized uptake value) techniques.

top of page

Publication History

Cite this article as

Corresponding author e-mail